INNOCARE Aktie

 

ICP-B208 is InnoCare's second ADC from its in-house platform to enter clinical development. There are no approved CDH17 targeted ADCs globally....

The study showed that orelabrutinib was safe and well tolerated in participants with SLE....

InnoCare's novel BCL2i mesutoclax in MDS and AML was released at 2026 ASCO as an oral presentation, demonstrating outstanding efficacy and safety....

This is the first NDA acceptance for BTK inhibitor orelabrutinib in autoimmune diseases. No BTK inhibitors have been approved in China for ITP....

INNOCARE (09969.HK) announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted the new drug application in China for the Brutons tyrosine kinase (BTK) inhibitor orelabrutinib, indicated for the treatment of patients with primary immune thrombocytopenia (ITP). (sl/a)~AA......

Orelabrutinib (HIBRUKA®) has been approved by TGA in Australia, offering a new treatment option for patients with R/R MCL in the region....

INNOCARE (09969.HK) announced that orelabrutinib (Hibruka) has been approved by the Therapeutic Goods Administration (TGA) in Australia for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (r/r MCL). (jl/a)~AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated b......

The data show that mesutoclax demonstrates outstanding efficacy and safety in treating various hematologic malignancies....

- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ICP-054 (ZB021) in healthy volunteers - Phase 1 SAD and MAD data expected by year-end 2026...

ICP-488 is expected to provide a novel therapeutic option for patients. There are no approved targeted therapies for Sjögren's syndrome globally....

The IND approval marks another milestone in our solid tumor pipeline and validates the huge drug development potential of our ADC platform....

Orelabrutinib is the first BTKi to demonstrate significant efficacy in a Phase II clinical trial for SLE, which affects around 8 million people worldwide....

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

InnoCare remained profitable in the first quarter of 2026, with net profit increasing by 607.7% YoY to RMB 102.4 million....

G Sachs released a research report indicating that INNOCARE (09969.HK) achieved RMB390 million in sales for Orelabrutinib in the fourth quarter of last year, representing a 27% YoY increase. The sales for 2025 are expected to rise by 41% YoY, aligning with the company's previous guidance. Due to approximately RMB837 million in c......

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

INNOCARE PHARMA (09969.HK) announced its 2025 annual results, reporting revenue of RMB2.375 billion, representing a year-on-year increase of 135.3%. The company recorded a net profit of RMB642 million, compared to a loss of RMB441 million in the previous year, turning from loss to profit; earnings per share were RMB0.38. No fina......

BEIJING, March 25, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual results for 2025 as of December 13, 2025....

BEIJING, March 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first healthy volunteer has been dosed in a clinical trial of ICP-538, a VAV1-directed molecular glue degrader (MGD), in China. This is the first VAV1 degrader approved to enter clinical trials in China and the second globally....

InnoCare Optoelectronics is expanding its global service network to capture growth from rising regional economies. Chairman James Yang said the company has entered India with localized manufacturing to reduce tariff barriers while addressing demand for healthcare digitalization. In the Americas, InnoCare has established local repair centers to provide immediate technical support and after-sales services, strengthening customer service and market share across regional markets....